Characterization of camptothecin-resistant Chinese hamster lung cells

Area of Science:

• Cell Biology
• Molecular Pharmacology
• Cancer Research

Background:

• Camptothecin (CPT) is a potent anticancer agent targeting DNA topoisomerase I.
• Understanding CPT resistance mechanisms is crucial for optimizing cancer chemotherapy.
• Development of drug-resistant cell lines aids in elucidating resistance pathways.

Purpose of the Study:

• To investigate the biochemical mechanisms underlying camptothecin (CPT) resistance in V79 cell sublines.
• To explore potential collateral sensitivity or resistance to other chemotherapeutic agents in CPT-resistant cells.
• To evaluate the implications for combination cancer therapy strategies.

Main Methods:

• Stepwise, continuous exposure of V79 cells to CPT to generate resistant sublines (V79r, IRS-1r, IRS-2r).
• Biochemical characterization of resistant cell lines to assess CPT intracellular accumulation, DNA topoisomerase I levels, and enzyme sensitivity.
• Evaluation of collateral sensitivity to etoposide (VP-16) and its analogue in resistant cell lines with normal DNA topoisomerase II levels.

Main Results:

• Developed three distinct camptothecin-resistant V79 cell sublines with varying degrees of resistance.
• Identified potential resistance mechanisms including decreased CPT accumulation, reduced DNA topoisomerase I levels, or decreased enzyme sensitivity to CPT.
• Observed collateral sensitivity to etoposide (VP-16) in resistant cells with down-regulated DNA topoisomerase I, despite similar DNA topoisomerase II levels.

Conclusions:

• DNA topoisomerase I alterations play a significant role in camptothecin resistance.
• Collateral sensitivity to etoposide in CPT-resistant cells suggests potential for combination therapy.
• Alternating CPT and VP-16 treatment may be a viable strategy for overcoming drug resistance in cancer therapy.